

Lissitchkov T, Willemze A, Katragadda S, et al. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. *Blood Adv.* 2022;6(4):1089-1094.

In Table 1 on page 1091, the heading for column 2 should read “Cohort 1 (50 IU/kg efanesoctocog alfa)” and the heading for column 3 should read “Cohort 2 (65 IU/kg efanesoctocog alfa).”

The same corrections apply to the headings in Table 2 on page 1093.

The errors have been corrected in the published article.

---

DOI 10.1182/bloodadvances.2022007724

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.